APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy

APOBEC mutagenesis underlies somatic evolution and accounts for tumor heterogeneity in several cancers, including breast cancer (BC). In this study, we evaluated the characteristics of a real-world cohort for time-to-treatment discontinuation (TTD) and overall survival on CDK4/6 inhibitors (CDK4/6i)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sammons, Sarah, Raskina, Kira, Danziger, Natalie, Alder, Laura, Schrock, Alexa B., Venstrom, Jeffrey M., Knutson, Keith L., Thompson, E. Aubrey, McGregor, Kim, Sokol, Ethan, Chumsri, Saranya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666120/
https://www.ncbi.nlm.nih.gov/pubmed/36315915
http://dx.doi.org/10.1200/PO.22.00149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666120/
https://www.ncbi.nlm.nih.gov/pubmed/36315915
http://dx.doi.org/10.1200/PO.22.00149

Ejemplares similares